RARE Ultragenyx Pharmaceutical Inc.

58.65
+1.78  (+3%)
Previous Close 56.87
Open 57.56
Price To Book 4.13
Market Cap 3,383,633,278
Shares 57,691,957
Volume 291,895
Short Ratio
Av. Daily Volume 430,246

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 third cohort data due 3Q 2019.
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Approved under priority review November 15, 2017.
MEPSEVII (vestronidase alfa)
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 data released October 26, 2018 - endpoints not met.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data released August 22, 2017 - endpoints not met.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Approval announced April 17, 2018.
Crysvita (Burosumab)
X-Linked Hypophosphatemia (XLH)
Data released September 2018.
KRN23 Burosumab
Tumor-induced osteomalacia (TIO)
NDA filing announced August 1, 2019.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
sBLA filing for children due 2H 2019.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
Phase 1/2 data from second cohort due 3Q 2019.
DTX401
GSD1

Latest News

  1. This Biotech Stock Just Roped In A New Partner — And A Potential Buyout
  2. Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome
  3. Ultragenyx to Present at Wedbush PacGrow Healthcare Conference
  4. Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
  5. Edited Transcript of RARE earnings conference call or presentation 1-Aug-19 9:00pm GMT
  6. Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
  7. Ultragenyx Pharmaceutical Inc (RARE) Q2 2019 Earnings Call Transcript
  8. Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
  9. Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update
  10. Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
  11. Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  12. Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update
  13. Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is A Financially Healthy Company
  14. Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
  15. Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
  16. Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
  17. Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
  18. Here’s What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE)
  19. Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
  20. See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.